The clinical validation of albumin as an effective drug carrier is exemplified by the success of nab-paclitaxel (albumin-bound paclitaxel, Abraxane®), which has demonstrated superior efficacy and reduced toxicity compared with solvent-based paclitaxel in multiple cancer types, including TNBC [25]. The gene discussed is ALB; the disease is cancer.